UK-based Mundipharma has made steps towards its goals of becoming a leader in the biosimilars field, it has announced this week. It announced on Tuesday that it had secured a distribution licence from South Korea’s Celltrion for Truxima, a biosimilar of Roche's (ROG: SIX) blockbuster drug MabThera (rituximab). This biosimilar received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use last week for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. These are all of the indications of the reference biologic.
If approved, Truxima would be the first rituximab biosimilar approved by the European Commission. Mundipharma and its network of independent associated companies will have exclusive rights to market and distribute Truxima in the UK, Germany, Italy, Ireland, Belgium, Luxembourg and the Netherlands.
It will be the second biosimilar monoclonal antibody to be marketed and distributed by the Mundipharma network.
The company’s managing director Antony Mattessich said: “Mundipharma is establishing itself as a leader in biosimilars with our deep understanding of European markets and track record in delivering marketing excellence in a complex area.
“Biosimilar rituximab has an enormous potential to deliver patient benefits while freeing up resources for novel cancer treatment options. That’s why biosimilars are becoming a key part of our business in Europe and we look forward to building on our partnership with Celltrion and continuing to identify further partnerships in this area.”
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes
April 24th 2025Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.